Koustoulidou et al., 2022 - Google Patents
Synthesis and evaluation of two long-acting SSTR2 antagonists for radionuclide therapy of neuroendocrine tumorsKoustoulidou et al., 2022
View HTML- Document ID
- 16869899983784961758
- Author
- Koustoulidou S
- Handula M
- de Ridder C
- Stuurman D
- Beekman S
- de Jong M
- Nonnekens J
- Seimbille Y
- Publication year
- Publication venue
- Pharmaceuticals
External Links
Snippet
Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a promising antagonist peptide to target SSTR2. However, due to its rapid blood clearance, a better …
- 239000005557 antagonist 0 title abstract description 14
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sauerwein et al. | Theranostics in boron neutron capture therapy | |
| Varasteh et al. | The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin | |
| Mitran et al. | Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer | |
| Hu et al. | Radiosynthesis and preclinical evaluation of bispecific PSMA/FAP heterodimers for tumor imaging | |
| Lundmark et al. | Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—Optimization of the affinity towards PSMA by linker modification in murine model | |
| Bendre et al. | Evaluation of Met-Val-Lys as a renal brush border enzyme-cleavable linker to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides and peptidomimetics | |
| Vorobyeva et al. | Radionuclide molecular imaging of EpCAM expression in triple-negative breast cancer using the scaffold protein DARPin Ec1 | |
| Effendi et al. | Development of radiogallium-labeled peptides for platelet-derived growth factor receptor β (PDGFR β) imaging: Influence of different linkers | |
| Maschauer et al. | In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study | |
| Maschauer et al. | Theranostic value of multimers: lessons learned from trimerization of neurotensin receptor ligands and other targeting vectors | |
| Nock et al. | [99mTc] Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes | |
| Tolmachev et al. | Direct in vivo comparison of 99mTc-labeled scaffold proteins, DARPin G3 and ADAPT6, for visualization of HER2 expression and monitoring of early response for trastuzumab therapy | |
| Summer et al. | Pretargeted imaging with Gallium-68—improving the binding capability by increasing the number of tetrazine motifs | |
| Matalińska et al. | Novel NK1R-Targeted 68Ga-/177Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure–Activity Relationships | |
| Liu et al. | Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain | |
| Grob et al. | Improved tumor-targeting with peptidomimetic analogs of minigastrin 177Lu-PP-F11N | |
| Chapeau et al. | [212Pb] Pb-eSOMA-01: a promising radioligand for targeted alpha therapy of neuroendocrine tumors | |
| Milot et al. | 64Cu-DOTHA2-PSMA, a novel PSMA PET radiotracer for prostate cancer with a long imaging time window | |
| Lundmark et al. | Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation | |
| Jiang et al. | Development and evaluation of a peptide heterodimeric tracer targeting CXCR4 and integrin αvβ3 for pancreatic cancer imaging | |
| Lo et al. | Molecular imaging and preclinical studies of radiolabeled long-term RGD peptides in U-87 MG tumor-bearing mice | |
| Oroujeni et al. | Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3 | |
| Wang et al. | 68Ga-Labeled [Thz14] Bombesin (7–14) analogs: Promising GRPR-targeting agonist PET tracers with low pancreas uptake | |
| Liu et al. | Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting affibody molecule 188Re-ZHER2: 41071 | |
| Fani et al. | Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation—Preclinical assessment of two optimized candidates |